TCGA-E2-A1IK-01A-11R-A144-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 60
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.460
- OXIDATIVE_PHOSPHORYLATION+0.450
- INTERFERON_GAMMA_RESPONSE+0.360
- ALLOGRAFT_REJECTION+0.350
- FATTY_ACID_METABOLISM+0.290
- ADIPOGENESIS+0.280
- ESTROGEN_RESPONSE_LATE+0.230
- BILE_ACID_METABOLISM+0.220
- PEROXISOME+0.190
- PANCREAS_BETA_CELLS+0.180
Top 10 suppressed
- E2F_TARGETS-0.480
- G2M_CHECKPOINT-0.480
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.470
- MITOTIC_SPINDLE-0.410
- APICAL_JUNCTION-0.290
- TGF_BETA_SIGNALING-0.280
- UV_RESPONSE_DN-0.280
- MYC_TARGETS_V2-0.270
- ANGIOGENESIS-0.210
- MYC_TARGETS_V1-0.170
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-OR-A5LH-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.888 |
| 2 | ERR2208921 | — | — | 0.814 |
| 3 | SRR8518337 | — | F | 0.805 |
| 4 | SRR8943014 | — | — | 0.804 |
| 5 | C3N-00572 | — | cohortA1 | 0.802 |
| 6 | MDT-AP-2075 | Med | Medulloblastoma | 0.795 |
| 7 | 5ed0377f-26aa-4b4c-bb59-03001895aecd | — | — | 0.784 |
| 8 | TCGA-67-3770-01A-01R-0946-07 | — | cohortA1 | 0.781 |
| 9 | TCGA-05-5423-01A-01R-1628-07 | — | cohortA1 | 0.780 |
| 10 | TCGA-BH-A6R8-01A-21R-A33J-07 | — | B | 0.768 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.460 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.450 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.360 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.350 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.290 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.280 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.230 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.220 | Inavolisib | — uncovered |
| PEROXISOME | 0.190 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.180 | Cobimetinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.170 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.160 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.150 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.140 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.140 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.140 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.130 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.120 | Temsirolimus | — uncovered |
| P53_PATHWAY | 0.120 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.110 | Inavolisib | — uncovered |